USA financial news

Glenmark Prescribed drugs acquires sure OTC medication from Wockhardt in US

Glenmark Prescribed drugs Ltd on Tuesday mentioned it has acquired the authorised generic variations of sure over-the-counter medication from Wockhardt Ltd within the US.

The acquisition by the corporate’s fully-owned subsidiary Glenmark Prescribed drugs Inc, USA consists of the authorised abbreviated new drug purposes (ANDAs) for famotidine tablets, 10 mg and 20 mg used to deal with and stop ulcers within the abdomen and gut, the corporate mentioned in a press release.

The corporate, nonetheless, didn’t disclose the monetary particulars.

Glenmark has additionally acquired ANDAs of anti-allergy medication cetirizine hydrochloride tablets, 5 mg and 10 mg, indigestion, heartburn and acid reflux disorder therapy drug Lansoprazole delayed-release capsules USP, 15 mg and Olopatadine Hydrochloride Ophthalmic Answer USP, 0.1 per cent indicated for allergic conjunctivitis and allergic rhinitis, within the US.

“The over-the-counter market has lengthy been an essential phase of Glenmark’s portfolio around the globe. Our acquisition of those ANDAs represents the continued growth of our enterprise into the OTC market right here in the US and our dedication to making sure sufferers have entry to top quality, inexpensive medicines,” Glenmark Prescribed drugs Inc, USA, President Sanjeev Krishan mentioned.

Glenmark mentioned its present portfolio consists of 175 merchandise authorised for distribution within the US market and 48 ANDAs pending approval with the USFDA.

(Solely the headline and film of this report could have been reworked by the Enterprise Normal workers; the remainder of the content material is auto-generated from a syndicated feed.)

Pricey Reader,

Enterprise Normal has all the time strived laborious to supply up-to-date data and commentary on developments which are of curiosity to you and have wider political and financial implications for the nation and the world. Your encouragement and fixed suggestions on find out how to enhance our providing have solely made our resolve and dedication to those beliefs stronger. Even throughout these tough occasions arising out of Covid-19, we proceed to stay dedicated to conserving you knowledgeable and up to date with credible information, authoritative views and incisive commentary on topical problems with relevance.

We, nonetheless, have a request.

As we battle the financial influence of the pandemic, we want your help much more, in order that we are able to proceed to give you extra high quality content material. Our subscription mannequin has seen an encouraging response from a lot of you, who’ve subscribed to our on-line content material. Extra subscription to our on-line content material can solely assist us obtain the targets of providing you even higher and extra related content material. We consider in free, honest and credible journalism. Your help by way of extra subscriptions might help us practise the journalism to which we’re dedicated.

Help high quality journalism and subscribe to Enterprise Normal.

Digital Editor

Related posts

OptMed IPO Replace: OMED Begins $24 Million U.S. IPO Effort


Inflation ‘coverage errors of the Seventies echo in our occasions,’ Monetary Instances columnist warns


Jobless claims present U.S. unemployment stays at pandemic low